Given that one of the most frequently amplified genes in DIPG is PDGFRA, PDGFR-targeted therapies, including agents such as imatinib and dasatinib, have been investigated, unfortunately resulting in poor antitumor effects [15]. The gene discussed is PDGFRB; the disease is diffuse intrinsic pontine glioma.